Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A known ✓ | P37088 | 1/20 | 0.90 |
| ▸ | PLAU | P00749 | 12/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.90 |
| ▸ | GLA | P06280 | 3/20 | 0.90 |
| ▸ | HPGD | P15428 | 3/20 | 0.90 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.90 |
| ▸ | THRB | P10828 | 1/20 | 0.90 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.90 |
| ▸ | SLC9A5 | Q14940 | 5/20 | 0.90 |
| ▸ | TSHR | P16473 | 4/20 | 0.90 |
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.90 |
| ▸ | GAA | P10253 | 2/20 | 0.90 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.90 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.90 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.90 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiloride SCHEMBL136682 | 0.98 | PLAU (0.93) | PLAUCYP1A2ALDH1A1KDM4EGLA | |
| Amiloride SCHEMBL27563 | 0.95 | PLAU (1.00) | PLAUCYP1A2ALDH1A1KDM4EGLA | |
| Amiloride SCHEMBL29531132 | 0.95 | PLAU (1.00) | PLAUCYP1A2ALDH1A1KDM4EGLA | |
| Amiloride SCHEMBL4155066 | 0.93 | ALDH1A1 (1.00) | PLAUCYP1A2ALDH1A1KDM4EGLA | |
| SCHEMBL2690754 | 0.86 | PLAU (0.83) | PLAUCYP1A2ALDH1A1KDM4EGLA | |
| SCHEMBL13902826 | 0.81 | PLAU (0.75) | PLAUCYP1A2ALDH1A1KDM4EGLA | |
| SCHEMBL14153334 | 0.81 | PLAU (0.75) | PLAUCYP1A2ALDH1A1KDM4EGLA | |
| SCHEMBL15033062 | 0.81 | PLAU (0.75) | PLAUCYP1A2ALDH1A1KDM4EGLA | |
| SCHEMBL10087514 | 0.80 | PLAU (0.73) | PLAUCYP1A2ALDH1A1KDM4EGLA | |
| SCHEMBL13104159 | 0.79 | PLAU (0.71) | PLAUCYP1A2ALDH1A1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2025133218-A1 | PYRAZINE DERIVATIVES FOR THE TREATMENT OF SKIN DISORDERS | PHAMRI NORDEN AB (SE) | 2025-06-26 | — | — | WO | disclosed |
| US-20250002463-A1 | NEW SALT FORMS OF AMILORIDE AND ITS DERIVATIVES FOR PHARMACEUTICAL USE | PSOMRI HOLDING AB (SE) | 2025-01-02 | — | — | US | disclosed |
| EP-4408826-A1 | NEW SALT FORMS OF AMILORIDE AND ITS DERIVATIVES FOR PHARMACEUTICAL USE | Psomri Holding AB (SE) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023052449-A1 | NEW SALT FORMS OF AMILORIDE AND ITS DERIVATIVES FOR PHARMACEUTICAL USE | PSOMRI HOLDING AB (SE) | 2023-04-06 | — | — | WO | disclosed |
| US-11242555-B2 | Molecular sensors and uses thereof | NEW YORK UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210393645-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2021-12-23 | — | — | US | disclosed |
| EP-3459535-B1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-08-12 | — | — | EP | disclosed |
| US-20200155491-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2020-05-21 | — | — | US | disclosed |
| US-20200095627-A1 | MOLECULAR SENSORS AND USES THEREOF | NEW YORK UNIVERSITY | 2020-03-26 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100310641-A1 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2010-12-09 | — | — | US | disclosed |
| CN-101883561-A | Novel therapeutic methods for treating CMT and related diseases | PHARNEXT | 2010-11-10 | — | — | CN | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2211846-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | Pharnext (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-20100015127-A1 | TREATMENT FOR DEMYELINATING DISEASE | MEDICAL RESEARCH COUNCIL | 2010-01-21 | — | — | US | disclosed |
| WO-2009068668-A1 | NEW THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS | PHARNEXT (FR) | 2009-06-04 | — | — | WO | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | PHARMACIA CORPORATION (US) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | SCNN1A 2555/4885PLAU 1956/4885CYP1A2 1643/4885 |
| US-20100015127-A1 | TREATMENT FOR DEMYELINATING DISEASE | ASIC1, ASIC3, TRPM2 | SCNN1A 44/4885PLAU 4502/4885CYP1A2 4558/4885 |
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | NR3C2, REN, AGTR1 | SCNN1A 881/4885PLAU 1237/4885CYP1A2 240/4885 |
| US-20250002463-A1 | NEW SALT FORMS OF AMILORIDE AND ITS DERIVATIVES FOR PHARMACEUTICAL USE | ASIC1, PPA1, ASIC3 | SCNN1A 175/4885PLAU 1690/4885CYP1A2 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.